Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc has demonstrated a strengthened efficacy profile for its lead program TARA-002, with 6-month data showing improvements over initial 3-month results, indicating a 100% durability and an 80% salvage rate upon re-induction. Additionally, the Phase 2 trial of intravenous (IV) choline chloride revealed significant improvements in liver health compared to placebo, suggesting robust potential for this therapy in treating intestinal failure associated liver disease. The combination of TARA-002's safety and administration benefits, along with the promising trial results, positions the company favorably within the competitive landscape of treatment options for cancer and rare diseases.

Bears say

Protara Therapeutics Inc reported a significant net loss of $12.7 million, or $0.48 per share, in the fourth quarter of 2024, which raises concerns about its financial sustainability given its current cash burn rate. Despite early positive signals for TARA-002 in non-muscle invasive bladder cancer (NMIBC), the company's stock is trading at a steep discount compared to competitors, indicating potential investor skepticism about its long-term value. Furthermore, the limited efficacy of intravenous choline chloride in addressing intestinal failure-associated liver disease (IFALD) and its abundance in normal diets suggest challenges in differentiating the therapy in a competitive landscape, further contributing to a negative outlook for the stock.

TARA has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 8 analysts, TARA has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.